ADHD genetics reveal a web of overlapping brain pathways, not a single cause

Large genetic studies are mapping how thousands of variants shape ADHD risk, symptoms and overlap with other psychiatric conditions , but the findings are not yet ready for diagnosis.

Attention-deficit/hyperactivity disorder is increasingly being understood as a highly heritable neurodevelopmental condition rather than a simple problem of behaviour or self-control. Large genetic studies have shown that risk is spread across many common variants, each with a small effect, alongside rarer changes that may have larger influence. Taken together, these findings point to biology that begins early in brain development and is shaped by networks involved in attention, impulse control and executive function. The most recent review material linked to the Nature publication also reflects a broader shift in the field: researchers are moving away from searching for a single cause and towards mapping how many genetic signals combine to affect symptoms across the population.

The evidence base has expanded markedly over the past decade. A landmark 2019 study identified the first genome-wide significant risk loci for ADHD, marking an important step in moving the disorder into the era of common variant genetics. An updated meta-analysis in 2023 went further, analysing 38,691 people with ADHD and 186,843 controls, and reporting 27 genome-wide significant loci. That study also highlighted 76 potential risk genes, with strong expression during early brain development, and pointed to brain-specific neuronal subtypes, including midbrain dopaminergic neurons, as part of the disorder’s biological footprint.

These genetic findings matter because they help explain why ADHD so often overlaps with other psychiatric and neurodevelopmental conditions. The 2023 analysis found that a substantial share of ADHD-influencing variants are shared with other psychiatric disorders, reinforcing the idea that diagnostic labels can mask partly overlapping biology. Earlier work in psychiatric genetics had already shown that common risk is rarely unique to one condition, and ADHD appears to fit that pattern. The newer data also link common variant risk to reduced performance in complex cognitive domains, including verbal reasoning and executive functions such as sustained attention, which are central to everyday functioning.

The same research tradition is also reshaping how scientists think about the brain in ADHD. Imaging studies and broader neurobiological reviews have long suggested differences in large-scale brain networks linked to attention and cognitive control, but the field has struggled to translate those findings into simple clinical tests. More recent work is increasingly focused on combining genetic data with brain measures and behaviour. Studies cited alongside the Nature publication describe polygenic scores predicting attention problems in children, associations with white matter microstructure, and efforts to identify brain-based subtypes that could one day help guide treatment. In parallel, other research has examined how ADHD-related genetic risk may intersect with traits such as impulsivity, sleep disturbance and even screen use, suggesting that the effects of inherited risk can be traced across several layers of development and behaviour.

The emerging picture is clinically important, but it is not yet ready for routine diagnosis. Polygenic scores can strengthen research, help define risk in large samples and improve understanding of why symptoms vary so widely, but they are not currently precise enough to replace clinical assessment. That caution matters, especially because ADHD is common, heterogeneous and often accompanied by other difficulties. Still, the direction of travel is clear: as genome-wide studies grow larger and brain-based methods become more sophisticated, researchers are getting closer to a more nuanced account of ADHD , one that treats it as a spectrum of overlapping biological pathways rather than a single disorder with a single cause.